Metabolic Tumor Volume in Lymphoma: Hype or Hope?
作者信息
Schöder Heiko, Moskowitz Craig
机构信息
Memorial Sloan Kettering Cancer Center, New York, NY.
出版信息
J Clin Oncol. 2016 Oct 20;34(30):3591-3594. doi: 10.1200/JCO.2016.69.3747.
Abstract
摘要
相似文献
1
Metabolic Tumor Volume in Lymphoma: Hype or Hope?淋巴瘤中的代谢肿瘤体积：炒作还是希望？
J Clin Oncol. 2016 Oct 20;34(30):3591-3594. doi: 10.1200/JCO.2016.69.3747.
2
Hope, hype, and cure: Ethics and four-letter words in pediatric cancer care.希望、炒作和治愈：儿科癌症护理中的伦理道德和四字词。
Pediatr Blood Cancer. 2024 Mar;71(3):e30804. doi: 10.1002/pbc.30804. Epub 2023 Dec 11.
3
The impact and influence of hope and hype in decision-making about health technologies.希望和炒作在卫生技术决策中的影响
Healthc Manage Forum. 2015 Sep;28(5):218-20. doi: 10.1177/0840470415588698. Epub 2015 Jul 1.
4
Precision medicine in diffuse large B-cell lymphoma: Hype or hope?弥漫性大B细胞淋巴瘤中的精准医学：炒作还是希望？
Eur J Cancer. 2016 Nov;68:22-26. doi: 10.1016/j.ejca.2016.08.025. Epub 2016 Sep 30.
5
Reply to Mini-HCVD plus inotuzumab plus or minus blinatumomab: Hype or hope?对小剂量环磷酰胺联合伊奈妥单抗加或不加博纳吐单抗的回应：炒作还是希望？
Cancer. 2019 Nov 1;125(21):3891-3892. doi: 10.1002/cncr.32385. Epub 2019 Jul 10.
6
Mini-HCVD plus inotuzumab plus or minus blinatumomab: Hype or hope?小剂量高强度化疗联合伊奈妥单抗加或不加博纳吐单抗：是炒作还是希望？
Cancer. 2019 Nov 1;125(21):3890-3891. doi: 10.1002/cncr.32381. Epub 2019 Jul 10.
7
Reality of complementary and alternative medicine in lymphoma patients: hope, hype, or help?淋巴瘤患者使用补充和替代医学的现状：希望、炒作还是帮助？
Am J Hematol. 2009 Dec;84(12):785-7. doi: 10.1002/ajh.21567.
8
Basal Cisternostomy: Hype or Hope?基底池造瘘术：炒作还是希望？
Neurol India. 2021 Mar-Apr;69(2):2-4. doi: 10.4103/0028-3886.314592.
9
AI-augmented multidisciplinary teams: hype or hope?人工智能增强的多学科团队：炒作还是希望？
Lancet. 2019 Nov 16;394(10211):1801. doi: 10.1016/S0140-6736(19)32626-1. Epub 2019 Nov 5.
10
Cannabis for Gastroparesis: Hype or Hope?用于治疗胃轻瘫的大麻：炒作还是希望？
Am J Gastroenterol. 2019 Jun;114(6):865-866. doi: 10.14309/ajg.0000000000000277.
引用本文的文献
1
Evaluation of prognostic risk factors of triple-negative breast cancer with F-FDG PET/CT parameters, clinical pathological features and biochemical indicators.基于F-FDG PET/CT参数、临床病理特征及生化指标评估三阴性乳腺癌的预后危险因素
Front Cell Dev Biol. 2024 Sep 4;12:1421981. doi: 10.3389/fcell.2024.1421981. eCollection 2024.
2
Comparison of the Accuracy of a Deep Learning Method for Lesion Detection in PET/CT and PET/MRI Images.PET/CT和PET/MRI图像中病变检测的深度学习方法准确性比较
Mol Imaging Biol. 2024 Oct;26(5):802-811. doi: 10.1007/s11307-024-01943-9. Epub 2024 Aug 14.
3
How to design a theranostic trial?如何设计一项治疗诊断试验？
Endocr Oncol. 2024 May 10;4(1):e230045. doi: 10.1530/EO-23-0045. eCollection 2024 Jan 1.
4
Radiomic signatures based on pretreatment 18F-FDG PET/CT, combined with clinicopathological characteristics, as early prognostic biomarkers among patients with invasive breast cancer.基于治疗前18F-FDG PET/CT的影像组学特征，联合临床病理特征，作为浸润性乳腺癌患者的早期预后生物标志物。
Front Oncol. 2023 Jul 27;13:1210125. doi: 10.3389/fonc.2023.1210125. eCollection 2023.
5
Quantitative PET-based biomarkers in lymphoma: getting ready for primetime.基于定量 PET 的淋巴瘤生物标志物：准备迎接黄金时代。
Nat Rev Clin Oncol. 2023 Sep;20(9):640-657. doi: 10.1038/s41571-023-00799-2. Epub 2023 Jul 17.
6
Pretreatment CT Texture Parameters as Predictive Biomarkers of Progression-Free Survival in Follicular Lymphoma Treated with Immunochemotherapy and Rituximab Maintenance.预处理CT纹理参数作为接受免疫化疗和利妥昔单抗维持治疗的滤泡性淋巴瘤无进展生存期的预测生物标志物。
Diagnostics (Basel). 2023 Jun 30;13(13):2237. doi: 10.3390/diagnostics13132237.
7
Development of a radiomic-clinical nomogram for prediction of survival in patients with diffuse large B-cell lymphoma treated with chimeric antigen receptor T cells.基于放射组学-临床列线图预测嵌合抗原受体 T 细胞治疗弥漫性大 B 细胞淋巴瘤患者生存情况的研究。
J Cancer Res Clin Oncol. 2023 Oct;149(13):11549-11560. doi: 10.1007/s00432-023-05038-w. Epub 2023 Jul 3.
8
Deep Learning-Based Segmentation and Volume Calculation of Pediatric Lymphoma on Contrast-Enhanced Computed Tomographies.基于深度学习的小儿淋巴瘤在对比增强计算机断层扫描上的分割与体积计算
J Pers Med. 2023 Jan 20;13(2):184. doi: 10.3390/jpm13020184.
9
Investigating and modeling positron emission tomography factors associated with large cell transformation from low-grade lymphomas.研究与低级淋巴瘤大细胞转化相关的正电子发射断层扫描因素并建立模型。
EJHaem. 2022 Nov 25;4(1):90-99. doi: 10.1002/jha2.615. eCollection 2023 Feb.
10
Prognostic value of F-FDG PET/CT radiomic model based on primary tumor in patients with non-small cell lung cancer: A large single-center cohort study.基于原发性肿瘤的F-FDG PET/CT影像组学模型在非小细胞肺癌患者中的预后价值：一项大型单中心队列研究
Front Oncol. 2022 Nov 17;12:1047905. doi: 10.3389/fonc.2022.1047905. eCollection 2022.
本文引用的文献
1
Kahl BS, Yang DT. Follicular lymphoma: evolving therapeutic strategies. Blood. 2016;127(17):2055-2063.卡尔·B·S、杨·D·T。滤泡性淋巴瘤：不断演变的治疗策略。《血液》。2016年；127(17):2055 - 2063。
Blood. 2016 Jul 21;128(3):463. doi: 10.1182/blood-2016-06-721902.
2
Baseline Metabolic Tumor Volume Predicts Outcome in High-Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies.基线代谢肿瘤体积可预测高肿瘤负荷滤泡性淋巴瘤的预后：三项多中心研究的汇总分析
J Clin Oncol. 2016 Oct 20;34(30):3618-3626. doi: 10.1200/JCO.2016.66.9440. Epub 2016 Sep 30.
3
Combined copy number and mutation analysis identifies oncogenic pathways associated with transformation of follicular lymphoma.拷贝数与突变联合分析确定了与滤泡性淋巴瘤转化相关的致癌途径。
Leukemia. 2017 Jan;31(1):83-91. doi: 10.1038/leu.2016.175. Epub 2016 Jun 16.
4
Molecular Profile and FDG-PET Metabolic Volume at Staging in DLBCL-Response.弥漫性大B细胞淋巴瘤（DLBCL）分期时的分子特征与氟代脱氧葡萄糖正电子发射断层扫描（FDG-PET）代谢体积——反应情况
Clin Cancer Res. 2016 Jul 1;22(13):3414-5. doi: 10.1158/1078-0432.CCR-16-0783.
5
Molecular Profile and FDG-PET/CT Total Metabolic Tumor Volume Improve Risk Classification at Diagnosis for Patients with Diffuse Large B-Cell Lymphoma.弥漫性大 B 细胞淋巴瘤患者的分子谱和 FDG-PET/CT 总代谢肿瘤体积改善了诊断时的风险分类。
Clin Cancer Res. 2016 Aug 1;22(15):3801-9. doi: 10.1158/1078-0432.CCR-15-2825. Epub 2016 Mar 2.
6
Combination of baseline metabolic tumour volume and early response on PET/CT improves progression-free survival prediction in DLBCL.基线代谢肿瘤体积与PET/CT早期反应相结合可改善弥漫性大B细胞淋巴瘤无进展生存期的预测。
Eur J Nucl Med Mol Imaging. 2016 Jul;43(7):1209-19. doi: 10.1007/s00259-016-3315-7. Epub 2016 Feb 23.
7
Prognostic value of baseline total metabolic tumor volume (TMTV0) measured on FDG-PET/CT in patients with peripheral T-cell lymphoma (PTCL).氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描（FDG-PET/CT）测量的基线总代谢肿瘤体积（TMTV0）对外周T细胞淋巴瘤（PTCL）患者的预后价值。
Ann Oncol. 2016 Apr;27(4):719-24. doi: 10.1093/annonc/mdw011. Epub 2016 Jan 19.
8
Prospective Study of 3'-Deoxy-3'-18F-Fluorothymidine PET for Early Interim Response Assessment in Advanced-Stage B-Cell Lymphoma.3'-脱氧-3'-18F-氟代胸腺嘧啶PET用于晚期B细胞淋巴瘤早期中期反应评估的前瞻性研究
J Nucl Med. 2016 May;57(5):728-34. doi: 10.2967/jnumed.115.166769. Epub 2015 Dec 30.
9
Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.在接受一线免疫化疗的滤泡性淋巴瘤患者中，基因突变更新预后风险预测：一项前瞻性临床试验的回顾性分析及基于人群的登记处验证。
Lancet Oncol. 2015 Sep;16(9):1111-1122. doi: 10.1016/S1470-2045(15)00169-2. Epub 2015 Aug 6.
10
Harmonizing FDG PET quantification while maintaining optimal lesion detection: prospective multicentre validation in 517 oncology patients.在保持最佳病灶检测的同时实现氟代脱氧葡萄糖正电子发射断层扫描（FDG PET）定量的一致性：对517例肿瘤患者进行的前瞻性多中心验证
Eur J Nucl Med Mol Imaging. 2015 Dec;42(13):2072-82. doi: 10.1007/s00259-015-3128-0. Epub 2015 Jul 30.
Zotero 插件